Cynosure Receives Additional Regulatory Approvals for Flagship Products in Asia Pacific
September 24 2009 - 8:30AM
PR Newswire (US)
Company Launches Smartlipo MPX Laser Lipolysis Workstation in
Korea; Secures Market Approval for Affirm Skin Rejuvenation
Technology in China WESTFORD, Mass., Sept. 24
/PRNewswire-FirstCall/ -- Broadening the reach of two of its
flagship aesthetic laser products into the Asia Pacific region,
Cynosure, Inc. (NASDAQ:CYNO) today announced that it has received
approval to market the Smartlipo MPX(TM) LaserBodySculpting(SM)
Workstation in Korea and the Affirm(TM) Anti-Aging Workstation in
the People's Republic of China. Smartlipo MPX is the world's
signature brand for precision body contouring; Affirm provides a
complete skin rejuvenation solution that targets all layers of
photodamaged and aged skin. "These approvals for Smartlipo MPX and
Affirm further our initiative to expand in the Asia Pacific region
as part of our international growth strategy," said Cynosure
President and Chief Executive Officer Michael Davin. "We believe
that the increasing economic prosperity of the middle class in
these countries is creating a vibrant base of aesthetically
conscious consumers and a corresponding demand from practitioners
eager to be trained on new procedures and techniques. By having
already established a direct sales presence in China and Korea, we
believe we are well positioned to capitalize on opportunities
through new product introductions in these dynamic markets."
Smartlipo MPX and Affirm are among Cynosure's most popular
workstations. Smartlipo MPX liquefies fat and tightens skin through
tissue coagulation. The novel Smartlipo MPX platform incorporates
the company's exclusive MultiPlex(TM) technology. MultiPlex
combines the benefits of the 1064-nm and 1320-nm wavelengths in a
single laser output, creating a blended thermal and photomechanical
effect. The Smartlipo MPX workstation can be configured with the
company's SmartSense with ThermaGuide, an intelligent energy
delivery system equipped with a thermal sensing cannula for
controlling temperatures in the subcutaneous areas of the body.
This technology allows the practitioner to set temperature
thresholds to achieve targeted, controlled energy delivery for a
safe and optimal clinical endpoint. The non-invasive Affirm
Anti-Aging Workstation offers the benefits of wrinkle reduction,
pigmentation and redness reduction, age spot treatment and overall
facial rejuvenation. The MultiPlex technology-equipped Affirm
enables the sequential emission of two wavelengths in one pulse
from the same delivery system, helping to maximize comfort and
achieve faster recovery time compared with single-wavelength
technologies. Affirm uses the 1440-nm Combined Apex Pulse(SM)
technology to target superficial layers of photodamaged tissue,
state-of-the-art Xenon Pulsed Light technology to enhance clinical
outcomes associated with the treatment of redness and pigmentation,
and 1320-nm MultiPlex technology to target deep layers of collagen
structures for skin laxity and tightening. About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems
that are used by physicians and other practitioners to perform
non-invasive and minimally invasive procedures to remove hair,
treat vascular and pigmented lesions, rejuvenate the skin, liquefy
and remove unwanted fat through laser lipolysis and temporarily
reduce the appearance of cellulite. Cynosure's products include a
broad range of laser and other light-based energy sources,
including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well
as intense pulsed light. Cynosure was founded in 1991. For
corporate or product information, contact Cynosure at 800-886-2966,
or visit http://www.cynosure.com/. Safe Harbor Any statements in
this press release about future expectations, plans and prospects
for Cynosure, Inc., including statements about the company's plans
within the People's Republic of China and Korea, as well as other
statements containing the words "believes," "anticipates," "plans,"
"expects," "will" and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including Cynosure's
reliance on sole source suppliers, the inability to accurately
predict the timing or outcome of regulatory decisions, changes in
consumer preferences, competition in the aesthetic laser industry,
economic, market, technological and other factors discussed in
Cynosure's most recent Annual Report on Form 10-K, which is filed
with the Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
Cynosure's views as of the date of this press release. Cynosure
anticipates that subsequent events and developments will cause its
views to change. However, while Cynosure may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Cynosure's views as of any date subsequent to the date
of this press release. Contact: Scott Solomon Vice President Sharon
Merrill Associates, Inc. 617.542.5300 DATASOURCE: Cynosure, Inc.
CONTACT: Scott Solomon, Vice President, Sharon Merrill Associates,
Inc. for Cynosure, Inc., +1-617-542-5300, Web Site:
http://www.cynosurelaser.com/
Copyright
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From Jul 2023 to Jul 2024